Table of Contents
- Chapter One: Executive Summary
- Report Scope
- Categories
- Methodology
- Product Description
- Overview
- Antiseptics
- Antibiotics
- Antifungal Treatments
- Anti-Parasitic (Lice) Treatments
- The Market
- Market Composition
- Key Trends & Issues
- Seasonality in Anti-fungal Treatment Sales
- Most Drugs Approved in 2004 Since 1996
- Lack of Rx-to-OTC Switches for Anti-infectives
- Growing Healthcare Costs
- The Online Healthcare Market
- Market Forecast
- The Marketers
- Private Labels
- The Consumer
- Chapter Two: The Market
- Product Description
- Overview
- Antiseptics
- Antibiotics
- Antibiotic Resistance
- Antifungal Treatments
- Introduction to Infections
- Jock Itch (Tinea Cruris)
- Vaginal Yeast Infection (Vulvovaginal Candidiasis)
- Athlete's Foot (Tinea Pedis)
- Antiparasitic (Lice) Treatments
- Regulatory Environment
- Brand and Generic Names
- The Cost Factor
- Approval Process
- OTC and Prescription Drugs
- Rx-to-OTC Switch
- Labeling Issues
- Industry Overview
- Market Composition
- Anti-fungal Treatment
- First Aid Products
- Anti-Parasitic Treatments
- Key Trends & Issues
- Seasonality in Antifungal Treatment Sales
- Number of New Drug Approvals
- More Botanicals, Fewer Preservatives
- Lack of Rx-to-OTC Switches for Anti-Infectives
- Growing Healthcare Costs
- Children -- A Key Demographic
- Growing Insurer Share in Healthcare
- Pharma's Revenue Expectations
- Importation of Drugs
- Growing Share of Uninsured Population
- Lower Drug Costs Through Outsourcing
- Consumer Acceptance of Self-Medication
- The Online Healthcare Market
- The Insurer Push
- Direct-to-Consumer Advertising
- The Growth of Generics
- Market Forecast
- Chapter Three: The Marketers
- Competitive Analysis
- Top Marketers and Products
- Antifungal Treatments
- Flat Sales for Jock Itch Brands
- Lotrimin Ultra Outperforms Category
- Monistat Dominates Yeast Infection Treatments
- Athlete's Foot -- Schering-Plough at the Top
- Antiseptics/Antibiotics
- Anti-Parasitics
- Private Labels
- Mergers & Acquisitions
- Pfizer Acquires Pharmacia Corp.
- Novartis AG - Eon Labs
- Novartis Acquires Vagistat from Bristol-Myers Squibb
- Mylan Laboratories Acquires King Pharmaceuticals
- Chapter Four: The Consumer
- Simmons Survey
- Overview
- First Aid
- First Aid Bandages
- Sprays, Gels & Wipes Emerging
- Band-Aid, The Consumer's Favorite
- Antifungal Treatments
- Foot and Nail Fungus
- Older Population
- Roper Public Affairs Survey
- Men more Likely to Suffer from Athlete's Foot
- Central and Pacific States Index Higher for Athlete's Foot
- Foot Problem Survey
- Athlete's Foot & Nail Fungus Treatment Users
- Yeast Infection
- Yeast Treatment Usage by Type
- African-American Women Index Higher
- Monistat Leads All
- Consumer Attitudes
- Preference for OTC Drugs and Private Labels
- Store Brand Buyers
- Chapter Five: Marketing Dynamics
- Overview
- Advertising and Promotion
- Pfizer Tops Ad Spend List
- Novartis' DTC Campaign
- Monistat Intimate Skincare Launch
- Distribution & Retailing
- Drug Store Chains
- e-Pharmacies
- Retail trends
- Drug Stores Outpace Overall Market
- Store Clinics
- Rite Aid Tests Hispanic Stores
- Drug Chains Aid Consumers
- Pharmacy Recommendations
- Walgreens' Health Initiatives
- New Product Introductions
- Consumers Prefer Quick-Relief & Natural Products
- First Aid for Kids
- Limited Yeast Infection Products
- Hypoallergenic Anti-Infectives
- Scented/Flavored Products
- Innovation
- Chapter Six: Company Profiles
- Johnson & Johnson
- Overview
- OTC Anti-Infective Product Line
- Band-Aid
- Monistat
- Performance
- Pfizer Inc.
- Overview
- OTC Anti-Infective Product Line
- Focus on Pharmaceuticals and Healthcare
- Performance
- Bayer Group
- Overview
- U.S. Operations
- OTC Anti-Infective Product Line
- Performance
- Bayer, Expanding its Reach
- Bristol-Myers Squibb Company
- Overview
- OTC Anti-Infectives
- Performance
- Renewed Strategy - Focus on Prescription Drugs
- Novartis AG
- Overview
- The Consumer Health Division
- OTC Anti-Infective Product Line
- Performance
- R&D: The Company's Lifeblood
- Schering Plough Corporation
- Overview
- OTC Anti-Infective Product Line
- Performance
- Combe Inc.
- Overview
- OTC Anti-Infective Product line
- Performance
- Chattem Inc.
- Overview
- OTC Anti-Infective Product Line
- Performance
- Merz Pharmaceuticals
- Beiersdorf AG
- Overview
- OTC Anti-Infective Product Line
- Performance
- Taro Pharmaceuticals Industries Ltd.
- Overview
- R&D
- Drug Portfolio
- Performance
- FDA Approves Taro's Mupirocin Ointment
- Stiefel Laboratories Inc.
- Overview
- Skin Care Products
- Sarna #1 Itch Relief Cream for 3 Years
- Performance
- FDA Approval for MimyX Cream
- Alva-Amco Pharmacal Companies Inc.
- Overview
- Product Portfolio
- Performance
- FungiCure 2004 Nail Hygiene Survey
- Becton Dickinson & Company
- Overview
- Anti-Infective Products
- Performance
- FDA Approval for BD Diagnostic Products
- Playtex Products Inc.
- Overview
- Product Portfolio
- Performance
- Core Category Acquisitions
- Appendix: Addresses of Select Marketers
- List of Exhibits
- Chapter One: Executive Summary
- Table 1-1: U.S. Retail OTC Anti-Infective Sales 2000-2005
- Table 1-2: IRI-Tracked Retail Anti-Infective Category Sales 2005
- Table 1-3: IRI-Tracked Retail Sales of U.S. Top 10 Anti-Infective
Marketers 2004-2005
- Table 1-4: IRI-Tracked Retail Sales of U.S. Top 10 Anti-Infective Brands
2004-2005
- Chapter Two: The Market
- Table 2-1: Stages in Clinical Trial
- Figure 2-1: U.S. Drug Development and Patent Process
- Figure 2-2: U.S. OTC Review Process
- Figure 2-3: U.S. Retail OTC Anti-infective Sales, 2000-2005 (E)
- Table 2-2: IRI-Tracked U.S. Retail Sales of OTC Anti-Infectives by
Category (Antifungals, First Aid, Antiparasitics) 2000-2005 (E)
- Table 2-3: IRI-Tracked U.S. Retail OTC Anti-Infective Category Shares
2000-2005 (E)
- Table 2-4: IRI-Tracked U.S. Retail Sales of OTC Antifungals by Infection
Type (Athlete's Foot, Jock Itch, Vaginal Yeast Infection) 2000-2005 (E)
- Figure 2-4: IRI-tracked U.S. Jock Itch and Athlete's Foot Quarterly
Sales, 2004-2005
- Table 2-5: U.S. Top 10 Cities Estimated to Experience Itch-Related
Infections, 2005
- Figure 2-5: U.S. FDA Drug Approvals, 1991-2004
- Figure 2-6: National Health Expenditure, 1993-2003
- Table 2-6: Projected U.S. Health Expenditures and Per Capita Income
2005-2010
- Table 2-7: Younger U.S. Population (Under 15 Years) Projections 2000-2030
- Table 2-8: Birth Rate and Women Age Group, 2002-2003
- Figure 2-7: Spending for Prescription Drugs by Source of Funds (%)
- Table 2-9: Uninsured Population by Age Group, 2003
- Table 2-10: U.S. Generic Drug vs. Branded Drug Performance
- Table 2-11: U.S. Top Five Generic Drug Marketers 2004 (Sales, Market
Share, Growth from 2003)
- Figure 2-8: U.S. Retail Anti-Infective Sales Projections, 2005-2010 (E)
- Table 2-12: U.S. Retail Anti-Infective Sales Projections by Category
2005-2010 (E)
- Chapter Three: The Marketers
- Table 3-1: IRI-Tracked Sales of Top 10 U.S. OTC Anti-Infective Marketers
2000-2005 (E)
- Figure 3-1: U.S. Top 10 OTC Anti-Infective Marketers by Market Share
2005 (E)
- Table 3-2: IRI-Tracked Sales of Top 10 U.S. OTC Anti-Infective Brands
2000-2005 (E)
- Table 3-3: IRI-Tracked Sales of Top 10 U.S. OTC Antifungal Marketers
2000-2005 (E)
- Table 3-4: U.S. Top 10 Antifungal Marketers by Market Share 2000-2005 (E)
- Table 3-5: IRI-Tracked Sales of Top 10 U.S. OTC Antifungal Brands
2000-2005 (E)
- Table 3-6: IRI-Tracked Sales of Top 10 U.S. OTC Jock Itch Treatment
Marketers, 2000-2005 (E)
- Table 3-7: U.S. Top 10 OTC Jock Itch Treatment Marketers by Market
Share, 2000-2005 (E)
- Table 3-8: IRI-Tracked Sales of Top 10 U.S. OTC Jock Itch Treatment
Brands 2000-2005 (E)
- Table 3-9: Top 10 Recognized Dermatology Brands in North America, 2005
- Table 3-10: IRI-Tracked Sales of Top 10 U.S.OTC Vaginal Yeast Infection
Treatment Marketers 2000-2005 (E)
- Table 3-11: U.S. Top 10 Vaginal Yeast Infection Treatment Marketers by
Market Share, 2000-2005 (E)
- Table 3-12: IRI-Tracked Sales of Top 10 U.S. OTC Vaginal Yeast Infection
Treatment Brands, 2000-2005 (E)
- Table 3-13: IRI-Tracked Sales of Top 10 U.S. OTC Athlete's Foot
Treatment Marketers, 2000-2005 (E)
- Table 3-14: U.S. Top 10 Athlete's Foot Treatment Marketers by Market
Share, 2000-2005 (E)
- Table 3-15: IRI-Tracked Sales of Top 10 U.S. OTC Athlete's Foot
Treatment Brands, 2000-2005 (E)
- Table 3-16: IRI-Tracked Sales of Top 10 U.S. OTC Antiseptic/Antibiotic
Marketers, 2000-2005 (E)
- Table 3-17: U.S. Top 10 Antiseptic/Antibiotic Marketers by Market Share,
2000-2005 (E)
- Table 3-18: IRI-Tracked Sales of Top 10 U.S. OTC Antiseptic/Antibiotic
Brands, 2000-2005 (E)
- Table 3-19: IRI-Tracked Sales of Top 10 U.S. OTC Anti-Parasitic
Treatment Marketers, 2000-2005 (E)
- Table 3-20: U.S. Top 10 Anti-Parasitic Treatment Marketers by Market
Share 2000-2005 (E)
- Table 3-21: IRI-Tracked Sales of Top 10 U.S. OTC Anti-Parasitic
Treatment Brands, 2000-2005 (E)
- Figure 3-2: U.S. Private Label OTC Anti-Infective Sales, 2000-2005 (E)
- Table 3-22: IRI-Tracked Sales of U.S. Private Label OTC Anti-Infectives
by Category (Antiseptics/Antibiotics, Anti-fungal Treatments, Antiparasitic
Treatments) 2000-2005 (E)
- Table 3-23: U.S. Private Label OTC Anti-Infective Market Share by
Category (Antiseptics/Antibiotics, Anti-fungal Treatments, Antiparasitic
Treatments) 2000-2005 (E)
- Chapter Four: The Consumer
- Figure 4-1: U.S. Usage of First Aid Products, 2004 (%)
- Figure 4-2: U.S. Usage of First Aid Products by Gender, 2005 (%)
- Table 4-1: U.S. Usage of First Aid Bandages by Age, 2005
- Table 4-2: U.S. Usage of First Aid Bandages, by Ethnicity, 2005
- Figure 4-3: U.S. Usage of First Aid Products by Type, 2005
- Table 4-3: U.S. Usage of First Aid Sprays, Gels and Wipes by Household
Size, 2005
- Table 4-4: U.S. Usage of First Aid Sprays, Gels and Wipes by Age of
Children, 2005
- Figure 4-4: U.S. First Aid Brands Used, 2005
- Table 4-5: Demographic Profile of U.S. First Aid Product Users, 2005
- Table 4-6: Demographic Profile of U.S. First Aid Cream, Gel and Liquid
Users, 2005
- Table 4-7: Demographic Profile of U.S. First Aid Ointment, Spray, Stick
and Wipe Users, 2005
- Table 4-8: Demographic Profile of U.S. First Aid Users by Brand, 2005
- Table 4-9: Demographic Profile of U.S. Store Brand First Aid Product
Users, 2005
- Table 4-10: U.S. Prevalence of Athlete's Foot by Age, 2005
- Figure 4-5: U.S. Prevalence of Athlete's Foot by Gender, 2005
- Figure 4-6: U.S. Prevalence of Nail Fungus by Gender, 2005
- Table 4-11: U.S. Prevalence of Athlete's Foot and Nail Fungus by
Ethnicity, 2005
- Table 4-12: U.S. Prevalence of Athlete's Foot and Nail Fungus by Region,
2005
- Table 4-13: U.S. Prevalence of Athlete's Foot and Nail Fungus by
Education, 2005
- Table 4-14: U.S. Foot Problem Prevalence, 2004
- Table 4-15: Demographic Profile of U.S. Athlete's Foot Treatment User,
2005
- Table 4-16: Demographic Profile of U.S. Nail Fungus Treatment User, 2005
- Table 4-17: Demographic Profile of U.S. Athlete's Foot-Infected
Consumer, 2005
- Table 4-18: Demographic Profile of U.S. Nail Fungus-Infected Consumer,
2005
- Table 4-19: Demographic Profile of U.S. Women Using Yeast Infection
Products, 2005
- Table 4-20: Yeast Infection Treatment by Type Preferred (1, 3, and
7-Day) 2005
- Table 4-21: Yeast Infection Treatment Usage by Ethnicity, 2005
- Figure 4-7: U.S. Yeast Infection Brands Used, 2005
- Table 4-22: Demographic Profile of U.S. Yeast Infection Treatment User
by Treatment Type, 2005
- Table 4-23: Demographic Profile of U.S. Yeast Infection Treatment User
by Brand, 2005
- Table 4-24: U.S. Consumer Attitudes w.r.t. Healthcare and Drugs, 2005
- Table 4-25: Demographic Profile of U.S. Consumers Based on Attitude
Towards Store Brands, 2004
- Chapter Five: Marketing Dynamics
- Table 5-1: Ad Spend of Top 10 U.S. OTC Anti-Infective Marketers 2004
- Table 5-2: Ad Spend and Media Channel of Top 10 U.S. OTC Anti-Infective
Brands 2004
- Table 5-3: U.S. Sales of Select OTC Anti-Infective Categories Through
Drug Stores 2004
- Table 5-4: Top Pharmacist Recommended Adhesive Bandages, 2005
- Table 5-5: Top Pharmacist Recommended Athlete's Foot Treatments, 2005
- Table 5-6: Top Pharmacist Recommended Jock Itch Treatments, 2005
- Table 5-7: Top Pharmacist Recommended Lice Treatments, 2005
- Table 5-8: Top Pharmacist Recommended Nail Fungus Treatments, 2005
- Table 5-9: Top Pharmacist Recommended Scar Treatments, 2005
- Table 5-10: Top Pharmacist Recommended Vaginal Antifungals, 2005
- Table 5-11: Top Pharmacist Recommended Wound Treatments, 2005
- Table 5-12: Top 10 Marketers by Total SKUs Launched, 2005
- Table 5-13: Top 10 Brands by Total SKUs Launched, 2005
- Table 5-14: Top 10 Package Tags by Number of Brands, 2005
- Table 5-15: U.S. Anti-Infective Product Introductions Tagged
'Instant/Quick', 2005
- Table 5-16: U.S. Anti-Infective Product Introductions Tagged
'Natural/Pure/Organic*', 2005
- Table 5-17: U.S. Anti-Infective Product Introductions for Teens/Kids,
2005
- Table 5-18: U.S. Anti-Infective Product Introductions Tagged 'Upscale',
2005
- Table 5-19: U.S. Anti-Infective Product Introductions for Women, 2005
- Table 5-20: U.S. Anti-Infective Product Introductions Tagged 'No
Allergy', 2005
- Table 5-21: U.S. Anti-Infective Product Introductions Tagged 'High
Vitamins', 2005
- Table 5-22: Top 10 OTC Anti-Infective Flavors/Fragrances, 2005
- Table 5-23: U.S. Anti-Infective Product Introductions Flavored/Scented
'Blend', 2005
- Table 5-24: U.S. Anti-Infective Product Introductions Flavored/Scented
'Lavender', 2005
- Table 5-25: U.S. Anti-Infective Product Introductions by Innovation, 2005
- Chapter Six: Company Profiles
- Table 6-1: Johnson & Johnson OTC Anti-Infective Brand Portfolio
- Figure 6-1: IRI-Tracked U.S. Anti-infective Sales of J ohnson & Johnson
2000-2005 (E)
- Table 6-2: Pfizer Inc. OTC Anti-infective Brand Portfolio
- Figure 6-2: Pfizer OTC Anti-infective Category Shares, 2005 (E)
- Figure 6-3: IRI-Tracked U.S. Anti-infective Sales of Pfizer Inc.,
2000-2005 (E)
- Table 6-3: Bayer OTC Anti-infective Brand Portfolio
- Figure 6-4: Bayer OTC Anti-infective Category Shares, 2005 (E)
- Figure 6-5: IRI-Tracked U.S. Anti-infective Sales of Bayer, 2000-2005 (E)
- Figure 6-6: IRI-Tracked U.S. Anti-infective Sales of Bristol-Myers
Squibb, 2000-2005 (E)
- Table 6-4: Novartis AG OTC Anti-infective Brand Portfolio
- Figure 6-7: IRI-Tracked U.S. Anti-infective Sales of Novartis AG,
2000-2005 (E) 198
- Table 6-5: Bayer Anti-infective Brand Portfolio
- Figure 6-8: Schering-Plough Corporation OTC Anti-infective Category
Shares, 2005 (E)
- Figure 6-9: IRI-Tracked U.S. Anti-infective Sales of Schering Plough,
2000-2005 (E)
- Table 6-6: Combe Inc. OTC Anti-infective Brand Portfolio
- Figure 6-10: Combe Inc. OTC Anti-infective Category Shares, 2005 (E)
- Figure 6-11: IRI-Tracked U.S. Anti-infective Sales of Combe Inc.,
2000-2005 (E)
- Figure 6-12: Chattem Inc. Business Segments as Percentage of Worldwide
Sales, 2004
- Figure 6-13: Chattem Inc. OTC Anti-infective Category Shares, 2005 (E)
- Figure 6-14: IRI-Tracked U.S. Anti-infective Sales of Chattem Inc.,
2000-2005 (E)
- Figure 6-15: IRI-Tracked U.S. Anti-infective Sales of Merz
Pharmaceuticals, 2000-2005 (E)
- Table 6-7: Beiersdorf Inc. OTC Anti-infective Brand Portfolio
- Figure 6-16: Beiersdorf Inc. OTC Anti-infective Category Shares, 2005 (E)
- Figure 6-17: IRI-Tracked U.S. Anti-infective Sales of Beiersdorf Inc.,
2000-2005 (E)
- Figure 6-18: IRI-Tracked U.S. Anti-infective Sales of Taro
Pharmaceuticals, 2000-2005 (E)
- Figure 6-19: IRI-Tracked U.S. Anti-infective Sales of Stiefel
Laboratories, 2000-2005 (E)
- Figure 6-20: IRI-Tracked U.S. Anti-infective Sales of Alva-Amco
Pharmacal, 2000-2005 (E)
- Table 6-8: Becton Dickinson Company Sales, by Region, 2004
- Table 6-9: Becton Dickinson Company Sales, by Division, 2004 Figure
6-21: IRI-Tracked U.S. Anti-infective Sales of Becton Dickinson, 2000-2005
(E)
- Table 6-10: Playtex Products Inc. Sales, by Division, 2004
- Figure 6-22: IRI-Tracked U.S. Anti-infective Sales of Playtex Products,
2000-2005 (E)
|
Related Report
|
View Cart
